Q3 2025 Medicover AB Earnings Call Transcript
Key Points
- Medicover AB (MCVEF) reported a strong Q3 2025 performance with a revenue growth of 12.1%, despite the exclusion of Hungary from the numbers.
- EBITDA increased by 32%, with an adjusted margin of 17.2%, showcasing solid financial health.
- Operating cash flow showed a positive movement of 36.7%, reaching EUR98.8 million, indicating strong cash generation.
- Healthcare Services experienced high organic growth, driven by increased capacity and asset utilization.
- Diagnostic Services reported a revenue increase of 17.8%, with strong demand from fee-for-service, contributing positively to the overall revenue stream.
- The exclusion of Hungary from the financials impacted the overall growth figures, necessitating adjustments for a clearer picture.
- The opening of new hospitals in India is expected to result in short-term profitability drains due to initial staffing and facility investments.
- A strike in Andhra Pradesh, India, affected hospital operations, potentially impacting Q4 results.
- There are early indications of cautious consumer behavior, which may affect revenue growth in certain segments.
- The integration of acquired businesses, particularly SYNLAB, is progressing slower than expected, affecting synergy realization.
Welcome to the Medicover Q3 2025 report presentation. (Operator Instructions) Now I will hand the conference over to the speakers, CEO, John Stubbington; and CFO, Anand Patel. Please go ahead.
Morning everybody. John here. Welcome to our Q3 report, and I'd like to start with thank you to all of our people for producing a really good result. So thank you for all your hard work. Q1, I described as strong, Q2, I described as stronger. I think Q3, what we're seeing here is a really good, solid, consistent and healthy performance.
If you look on the right hand side, you can see growth. It is a good performance at 12.1%, especially when you consider that Hungary no longer is in these numbers, so that's quite a pleasing position for us. If you look at EBITDA, it's very respectable, increase of 32%, which is really, really positive for us, and you can see that coming through, with the adjusted margin of 17.2%, moving up by 14.6% is really, really solid and quite an impressive performance by the team.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
